Fintel reports that on October 8, 2024, HC Wainwright & Co. upgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) from ...

Fintel reports that on October 7, 2024, HC Wainwright & Co. initiated coverage of DiaMedica Therapeutics (NasdaqCM:DMAC) with ...

Pharming Group (NASDAQ:PHAR – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They ...

Cassava Sciences (SAVA) stock earns its only buy rating on Wall Street as H.C. Wainwright upgrades the stock citing the company's recent SEC settlement. Read more here.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 65.69% ...

Equities research analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Rhythm Pharmaceuticals in ...

Fintel reports that on September 19, 2024, HC Wainwright & Co. upgraded their outlook for Prelude Therapeutics (NasdaqGS:PRLD) from Neutral to Buy. As of August 26, 2024, the average one-year price ...

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief ...

WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) ...

Fintel reports that on September 18, 2024, HC Wainwright & Co. initiated coverage of Rhythm Pharmaceuticals ( NasdaqGM:RYTM) with a Buy recommendation.

30, 2024 (GLOBE NEWSWIRE) -- BitFuFu, Inc. (NASDAQ: FUFU, FUFU.WS) (“BitFuFu” or the “Company”) a fast-growing digital asset mining service and world-leading cloud-mining service provider, today ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.